Fennec Pharmaceuticals Inc experienced notable price action this week, with a strong performance despite a recent dip.
Fennec Pharmaceuticals Inc (FRX.TO) has had a mixed week in stock performance, closing down 6.35% on Thursday after a notable rise of 10.95% over the past week. Investors are reacting to the company's recent financial results and strategic developments, which indicate growth potential in the health care sector.
Advertisement
Fennec Pharmaceuticals Inc
FRX.TO
FRX.TO
Fennec Pharmaceuticals Inc
WealthAwesomeAdvertisement
Market cap
$617.65M
52W high
$17.64
52W low
$7.59
1W change
+10.95%
Beta
1.07
Analyst Price Targets
Based on analyst covering FRX
Wall Street analysts forecast FRX stock price to rise 466.7% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$93.57
+466.7% Upside
Current Price
C$16.51
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Advertisement
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on FRX's historical volatility
30-Day Vol
63.0%
Annualized
90-Day Vol
80.0%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$19.74
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$17.52 | C$14.10 – C$21.78 |
| 60 trading days | C$18.60 | C$13.67 – C$25.29 |
| 90 trading days | C$19.74 | C$13.54 – C$28.77 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Despite the recent decline, Fennec's long-term growth outlook appears positive, supported by strong revenue growth and successful financial maneuvers. Investors should consider both the recent performance and the broader context of the company's financial health and market position.
Fennec Pharmaceuticals Reports 50% Increase in Annual Revenue
The company achieved net product sales of $44.6 million for the year, reflecting a 50% increase year-over-year, showcasing strong market performance.
Bull case
Fennec Pharmaceuticals has reported record annual revenue, with a significant increase in net product sales, indicating strong demand and acceptance of its product, PEDMARK®. The completion of debt redemption and positive cash flow are additional signs of financial health.
Bear case
The recent decline in share price may raise concerns among investors about market volatility. Additionally, the company's negative profit margin and return on equity could deter risk-averse investors.
Price Action Overview
This week, Fennec Pharmaceuticals Inc (FRX.TO) has shown some volatility. After closing at C$16.51 on Thursday, the stock saw a 1D decline of 6.35%. However, over the past week, it has gained 10.95%, reflecting a strong upward trend before the recent dip.
Company News and Catalysts
Advertisement
Fennec Pharmaceuticals recently reported record annual revenue, driven by net product sales of $44.6 million, marking a 50% increase year-over-year. The company also highlighted Q4 2025 net product sales of $13.8 million, a staggering 75% growth compared to the previous year. These results have attracted attention, as they indicate robust demand for their product, PEDMARK®. Furthermore, the completion of a full debt redemption totaling $21.7 million has strengthened the company's financial position.
Technical Picture
From a technical standpoint, Fennec Pharmaceuticals is currently trading above both its 50-day moving average of C$14.13 and its 200-day moving average of C$11.51, indicating a bullish trend. The stock has a 52-week range of C$7.59 to C$17.64, with current trading prices sitting at 89% of this range. With a beta of 1.07, the stock exhibits volatility that is slightly above the market average. Recent trading volume of 804 shares is slightly above the 20-day average of 788 shares, suggesting steady interest from investors.
Insider Activity
No recent insider activity has been reported for Fennec Pharmaceuticals, indicating that there have been no significant trades or transactions by company insiders that could influence market perception.
Price Action Summary
Fennec Pharmaceuticals Inc closed at C$16.51, reflecting a 1D decline of 6.35%. However, the stock has demonstrated strong growth over the past month, with a 1M gain of 11.63% and a year-to-date increase of 58.60%, suggesting a generally positive outlook despite recent fluctuations.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
